Faeth Therapeutics (FTH) Stock Price & Analysis

FTH Stock Chart & Stats

$18.69-$0.06(-0.32%)

At close: Oct 30 4:00 PM EDT

Day’s Range: $17.88 - $19.04
52-Week Range: $7.45 - $42.14
Previous Close: $18.75
Volume: N/A
Average Volume (3M): 379.15K
Market Cap: $482.96M
Enterprise Value: -$38.00M
Total Cash (Recent Filing): $186.44M
Total Debt (Recent Filing): $592.00K
Price to Earnings (P/E): ―
Beta: 2.25
Next Earnings: Nov 10, 2026 (Est.)
EPS Estimate: -0.78
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage

Minimal debt relative to equity reduces solvency pressure and interest-related constraints while preserving financial flexibility. This gives Faeth more capacity to fund development activities and manage setbacks, although it does not by itself create revenue or eliminate the need for future financing.

Improving Cash-flow Trend

The smaller recent free-cash-flow outflow suggests some improvement in cash discipline or development economics compared with the prior period. While Faeth remains cash-consuming, a sustained reduction in burn could extend funding runway and support continued pipeline advancement.

Experienced Oncology Governance

Adding a director with experience spanning oncology development, regulatory strategy and commercialization strengthens the expertise available for strategic decisions. That capability is relevant as Faeth advances metabolism-focused cancer therapeutics toward clinical and commercial milestones.

Bears Say

No Revenue Traction

The absence of sustained revenue indicates that Faeth has not yet established a commercial income stream from its therapeutic programs. This keeps the business dependent on development progress and external capital, increasing execution risk until candidates can generate meaningful recurring revenue.

Persistent Operating Losses

Persistent large losses show that current operations are not self-sustaining and that the pipeline has yet to translate into earnings power. Continued losses can constrain strategic flexibility, require additional funding and increase the consequences of delays in development or commercialization.

Ongoing Cash Burn And Funding Reliance

Negative operating and free cash flow across periods means Faeth cannot currently fund its activities from internally generated cash. Reliance on external capital may lead to financing pressure or shareholder dilution, particularly if pipeline spending continues before revenue begins.

Faeth Therapeutics News

Faeth Therapeutics Adds Oncology Expert to Board

Faeth Therapeutics ( ($FTH) ) just unveiled an announcement. On October 23, 2026, Faeth Therapeutics, Inc. expanded its Board of Directors from six to seven members and appointed Adam Schayowitz,

5d ago8K FTH

Faeth Therapeutics: Buy Rating Reiterated as Analyst Maintains Unchanged $60 Price Target Ahead of Key PIKTOR Data

H.C. Wainwright analyst Patrick Trucchio has reiterated their bullish stance on FTH stock, giving a Buy rating yesterday. Patrick Trucchio has given his Buy rating due to a combination of

5d agoFTH 4070

Faeth Therapeutics appoints Adam Schayowitz to board of directors

Faeth Therapeutics (FTH) announced the appointment of Adam Schayowitz, Ph.D., MBA, to its Board of Directors. Dr. Schayowitz is Executive Vice President and Head of Research and Development at Zymeworks

5d agoFTH ZYME

Faeth Therapeutics presents updated preclinical data on PIKTOR at ESMO

Faeth Therapeutics (FTH) announced presentation of preclinical data at the European Society for Medical Oncology Congress 2026 in Madrid, Spain, in a poster entitled “Characterising the efficacy of multi-node PI3K/AKT/mTOR

1w agoFTH 4070

Faeth Therapeutics to present preclinical data on PIKTOR at ESMO 2026

Faeth Therapeutics (FTH) will present preclinical data at the European Society for Medical Oncology Congress 2026 in Madrid, Spain. The poster will be presented on Friday, October 23, and will

1w agoFTH 4070

Faeth Therapeutics initiated with an Outperform at William Blair

William Blair initiated coverage of Faeth Therapeutics (FTH) with an Outperform rating. Faeth Therapeutics is an early clinical-stage oncology company developing novel therapies targeting the PI3K/AKT/mTOR, PAM, pathway, the analyst

2w agoFTH 4070

Faeth Therapeutics initiated with an Outperform at LifeSci Capital

LifeSci Capital initiated coverage of Faeth Therapeutics (FTH) with an Outperform rating and $40 price target Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news.

2w agoFTH 4070

Faeth Therapeutics management to meet with Oppenheimer

Meeting to be held in New York on October 13 hosted by Oppenheimer. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See

3w agoFTH 4070

Faeth Therapeutics Adds Cancer Expert to Board

The latest announcement is out from Faeth Therapeutics ( ($FTH) ). On September 11, 2026, Faeth Therapeutics, Inc. expanded its Board of Directors from five to six members and appointed

1M ago8K FTH

Faeth Therapeutics names Karen Vousden to board of directors

Faeth Therapeutics (FTH) “announced that Karen Vousden, Ph.D., has been appointed to its Board of Directors, effective September 11, 2026. Dr. Vousden is a cancer biologist recognized for her work

1M agoFTH 4070

Faeth Therapeutics initiated with a Buy at Guggenheim ahead of de-risking data

As previously reported, Guggenheim initiated coverage of Faeth Therapeutics (FTH) with a Buy rating and $70 price target The firm, which views PIKTOR Phase 2 data in endometrial cancer due

1M agoFTH 4070

Faeth Therapeutics initiated with a Buy at Guggenheim

Guggenheim analyst Brad Canino initiated coverage of Faeth Therapeutics (FTH) with a Buy rating and $70 price target Published first on TheFly – the ultimate source for real-time, market-moving breaking

1M agoFTH 4070

Faeth Therapeutics assumed with a Buy at Lucid Capital

Lucid Capital assumed coverage of Faeth Therapeutics (FTH) with a Buy rating and $59 price target The firm sees current share levels as offering an attractive risk/reward into the year-end

1M agoFTH 4070

Faeth Therapeutics Initiated at Buy on Oral Multi‑Node PI3K/AKT/mTOR Strategy; Analyst Sets $56 Price Target

Gil Blum, an analyst from Needham, has initiated a new Buy rating on Faeth Therapeutics (FTH). Gil Blum has given his Buy rating due to a combination of factors, centered

2M agoFTH 4070

FTH FAQ

What was Faeth Therapeutics’s price range in the past 12 months?

Faeth Therapeutics lowest stock price was $7.45 and its highest was $42.14 in the past 12 months.

What is Faeth Therapeutics’s market cap?

Faeth Therapeutics’s market cap is $482.96M.

When is Faeth Therapeutics’s upcoming earnings report date?

Faeth Therapeutics’s next earnings report is estimated for Nov 10, 2026 (not yet confirmed), which is in 8 days.

How were Faeth Therapeutics’s earnings last quarter?

Faeth Therapeutics released its earnings results on Aug 04, 2026. The company reported -$2.84 earnings per share for the quarter, missing the consensus estimate of -$2.636 by -$0.204.

Is Faeth Therapeutics overvalued?

According to Wall Street analysts Faeth Therapeutics’s price is currently Undervalued.

Does Faeth Therapeutics pay dividends?

Faeth Therapeutics does not currently pay dividends.

What is Faeth Therapeutics’s EPS estimate?

Faeth Therapeutics’s EPS estimate is -0.78.

How many shares outstanding does Faeth Therapeutics have?

Faeth Therapeutics has 25,840,425 shares outstanding.

What happened to Faeth Therapeutics’s price movement after its last earnings report?

Faeth Therapeutics reported an EPS of -$2.84 in its last earnings report, missing expectations of -$2.636. Following the earnings report the stock price went down -6.73%.

Which hedge fund is a major shareholder of Faeth Therapeutics?

Hedge funds hold Faeth Therapeutics shares: the largest hedge-fund position in Faeth Therapeutics is 70,144,182 shares, and hedge funds increased their holdings by 2.4M shares last quarter.

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Faeth Therapeutics Stock Smart Score

Outperform

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description